Jan. 19, 2007 -- The American Cancer Society issued its recommendations for
using the new vaccine against cervical
cancer -- recommendations that veer from those of other groups when
it comes to vaccinating women over 18.
The guidelines, published in the American Cancer Society's journal, CA:
A Cancer Journal for Clinicians, call for routinely vaccinating all girls
aged 11 to 12.
They add that the vaccine, called Gardasil, may be given to girls as young
Girls 13 to 18 should be given a "catch-up" vaccine if they never received
their vaccine, or did not complete the three-shot series.
However, unlike the CDC and the American College of Obstetricians and
Gynecologists, the American Cancer Society (ACS) does not recommend routine
vaccination for women 19 to 26.
"We don't believe the research is there among women 19 to 26 to justify
universal vaccine recommendation," says ACS guidelines co-author Mark Einstein,
MD, director of clinical research at Montefiore Medical Center and Einstein
College of Medicine in New York City.
More than 11,000 new cases of cervical cancer will be diagnosed in 2007,
with more than 3,600 deaths, according to ACS estimates.
The new cervical cancer vaccines, combined with new information about the
viral causes of cervical cancer, "present an unprecedented opportunity for
global cervical cancer prevention," say the ACS guidelines.
Gardasil protects against cervical cancer by preventing infection by the
human papillomavirus (HPV), the leading cause of cervical cancer.
HPV is a sexually transmitted virus, with dozens of strains.
But, according to ACS, two of those strains -- HPV 16 and 18 -- are
responsible for up to 70% of all cervical cancers.
Gardasil protects against four strains of HPV -- HPV 16 and 18, as well as
HPV 6 and 11, which account for 90% of genital
warts -- providing the woman has not been previously exposed.
And, says Einstein, therein lies the important caveat for women 19 to
"Studies show most women in this age group have had four or more sex
partners, meaning they have likely already been exposed to HPV," he says.
Since the vaccine will not work on those already infected, Einstein says it
was important for ACS to hold back from routinely recommending it in this age
"The recommendation is for women in this age group to talk to their doctor
about whether or not the vaccine can benefit them. But the research does not
justify universally recommending the vaccine," says Einstein.
Stephanie V. Blank, MD, a gynecologic oncologist at the NYU Cancer Institute
in New York City, disagrees.
While women aged 19 to 26 may benefit less from the vaccine, the shift away
from routine recommendations is likely to have more of a financial than a
medical advantage, Blank says.
"Giving the vaccine to a woman who has already been exposed is not going to
harm her -- and, in fact, it may help her, since it's unlikely that she would
have been exposed to all four of the cancer-related strains of HPV for which
the vaccine provides protection," says Blank.
Indeed, Blank tells WebMD that as long as a woman knows she needs to follow
up with regular screening Pap tests, whether she has been vaccinated or not,
"Those aged 19 to 26 should also be encouraged to get vaccinated." (All
cervical cancers are not caused by HPV.)